Prosecution Insights
Prosecution Insights
148 pending office actions • 102 clients • 130 examiners • 63 art units • 0 of 148 (0%) have an AI response strategy ready
Based on the USPTO statutory response window for each pending office action. 67 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 67 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 only | 1 (1%) |
| §101 + other | 11 (7%) |
| §103 only | 38 (26%) |
| §102 only | 6 (4%) |
| §112 only | 15 (10%) |
| Double-patenting only | 5 (3%) |
| Double-patenting + other | 10 (7%) |
| Multi-statute (no §101) | 61 (41%) |
| No statute on record | 1 (1%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| WALLENHORST, MAUREEN | 3 | 78.9% | +5.6% |
| REYNOLDS, FRED H | 3 | 33.1% | +39.0% |
| VIJAYARAGHAVAN, JAGAMYA NMN | 3 | 60.0% | +48.2% |
| KAUFMAN, CLAIRE M | 3 | 63.2% | +51.5% |
| COFFA, SERGIO | 2 | 61.2% | +33.1% |
| LEE, ANDREW P | 2 | 48.5% | +23.5% |
| FLINDERS, JEREMY C | 2 | 63.9% | +16.4% |
| CHANDRAKUMAR, NIZAL S | 2 | 72.7% | +18.3% |
| TRAN, CHRISTINA L | 2 | 48.2% | +45.5% |
| LEE, YIE CHIA | 2 | 71.9% | +45.6% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17629918 | ADOPTIVE TRANSFER OF PLASMACYTOID DENDRITIC CELLS TO PREVENT OR TREAT HAIR LOSS | MIANO, JOSEPH PAUL | 134d overdue |
| 18024179 | METHODS FOR IDENTIFYING CROSS-MODAL FEATURES FROM SPATIALLY RESOLVED DATA SETS | TRAN, DUY ANH | 132d overdue |
| 18014561 | COMPOSITIONS AND METHODS FOR TARGETING TUMOR ASSOCIATED TRANSCRIPTION FACTORS | GOMEZ RODRIGUEZ, JULIO WASHINGTON | 131d overdue |
| 17598029 | SYSTEMS AND METHODS FOR PRODUCING COLLAGEN 7 COMPOSITIONS | SABILA, MERCY HELLEN | 89d overdue |
| 15771043 | NOVEL POLYPEPTIDES WITH IMPROVED PROTEOLYTIC STABILITY, AND METHODS OF PREPARING AND USING SAME | REYNOLDS, FRED H | 73d overdue |
| 18379970 | APPARATUS AND METHOD FOR PRODUCING THREE-DIMENSIONAL OBJECTS | TAUFIQ, FARAH N | 58d overdue |
| 17440081 | CARDIOMYOCYTE PROLIFERATION | TRAN, KHOA NHAT | 37d overdue |
| 18039812 | RNA-TARGETING COMPOSITIONS AND METHODS FOR TREATING MYOTONIC DYSTROPHY TYPE 1 | VIJAYARAGHAVAN, JAGAMYA NMN | 31d overdue |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 15771043 | NOVEL POLYPEPTIDES WITH IMPROVED PROTEOLYTIC STABILITY, AND METHODS OF PREPARING AND USING SAME | REYNOLDS, FRED H | 73d overdue |
| 17939198 | THERAPEUTIC AGENT FOR KERATOCONJUNCTIVE DISORDERS | CHANDRAKUMAR, NIZAL S | 49d overdue |
| 18039812 | RNA-TARGETING COMPOSITIONS AND METHODS FOR TREATING MYOTONIC DYSTROPHY TYPE 1 | VIJAYARAGHAVAN, JAGAMYA NMN | 31d overdue |
| 17800639 | CXCL8 (INTERLEUKIN-8) ACTIVITY INHIBITOR AND CORTICOSTEROID COMBINATION AND PHARMACEUTICAL COMPOSITION AND USE THEREOF | LEE, ANDREW P | 19d overdue |
| 17637392 | COMPSTATIN ANALOGUES AND THEIR MEDICAL USES | COFFA, SERGIO | 3d overdue |
| 17735326 | COCHLEAR OUTER HAIR CELL PROMOTERS AND USES THEREOF | VIJAYARAGHAVAN, JAGAMYA NMN | 34d |
| 18140141 | METHODS OF TREATING LYMPHOPENIA | KAUFMAN, CLAIRE M | 60d |
| 17794673 | METHODS AND COMPOSITIONS FOR GENERATING TYPE 1 VESTIBULAR HAIR CELLS | TRAN, CHRISTINA L | 62d |
| Art Unit | Apps |
|---|---|
| 1658 | 8 |
| 1674 | 7 |
| 1647 | 5 |
| 1637 | 5 |
| 1684 | 5 |
| 1615 | 4 |
| 1617 | 4 |
| 1625 | 4 |
| 1628 | 4 |
| 1631 | 4 |
| App # | Title | Client | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|---|
| 19265435 | COMPOUNDS AND METHODS FOR TREATING MUSCULAR DYSTROPHY AND OTHER DISORDERS | The Charlotte Mecklenburg Hospital Authority D/B/A Atrium Health | DIAMOND, ALAN D | 3991 | DP | Non-Final OA | — | Pending | Jul 10, 2025 |
| 19117231 | SMALL-SIZE HIGH-VOLTAGE DIRECT CURRENT CONTACTOR | Kunshan Guoliyuantong New Energy Technology Co., Ltd. | HOMZA, LISA NHUNG | 2837 | §102§112 | Non-Final OA | — | Pending | Mar 31, 2025 |
| 19055839 | OPTICAL MICROSCOPY | Cambridge Enterprise Limited | COOK, JONATHON | 2877 | §103 | Non-Final OA | 36d | Pending | Feb 18, 2025 |
| 18980973 | MULTISENSOR BRACELET | Legionarius, LLC | HUNNINGS, TRAVIS R | 2689 | §102§103 | Non-Final OA | 22d | Pending | Dec 13, 2024 |
| 18850703 | THERAPEUTIC USES OF BRADYKININ B2-RECEPTOR ANTAGONISTS | Pharvaris GmbH | ROZOF, TIMOTHY R | 1629 | §102§112DP | Non-Final OA | — | Pending | Sep 25, 2024 |
| 18894251 | METHODS FOR LABELING URINE IN A SUBJECT WITH FLUOROPHORES | Uptru Inc. | WALLENHORST, MAUREEN | §102§103§112Other | Non-Final OA | — | Pending | Sep 24, 2024 | |
| 18829813 | TREATMENT OF URINARY INCONTINENCE | Axena Health, Inc. | ROBERTS, ANNA L | §103§112 | Non-Final OA | — | Pending | Sep 10, 2024 | |
| 18843373 | GPR120 AGONISTS FOR THE TREATMENT OF INFLAMMATORY BOWEL DISEASE | Dompe' Farmaceutici Spa | REDWOOD, CHRISTOPHER EVAN | DP | Non-Final OA | — | Pending | Sep 03, 2024 | |
| 18838347 | NEURAL PROGENITOR CELL COMPOSITIONS AND METHODS OF USING THE SAME | The General Hospital Corporation | KASAYAN, KATRIEL BARCELLANO | §101§103§112 | Non-Final OA | — | Pending | Aug 14, 2024 | |
| 18572977 | DEXMECAMYLAMINE AND USES THEREOF | Atacama Therapeutics, Inc. | ROCHELLE, CIERRA MARIE | §103 | Non-Final OA | — | Pending | Aug 13, 2024 | |
| 18835117 | ORAL SOLID PREPARATION | Kissei Pharmaceutical Co., Ltd. | GOTFREDSON, GAREN | 1615 | §103§112 | Non-Final OA | — | Pending | Aug 01, 2024 |
| 18769009 | RAS INHIBITORS | Revolution Medicines, Inc. | KIM, SEONG JONG | §112 | Non-Final OA | — | Pending | Jul 10, 2024 | |
| 18724295 | PEPTIDE HAVING ACTIVITY OF IMPROVING STATE OF SKIN, AND USE THEREOF | Caregen Co., Ltd. | HA, JULIE | §101 | Non-Final OA | — | Pending | Jun 26, 2024 | |
| 18724255 | PEPTIDE HAVING ACTIVITY OF IMPROVING STATE OF SKIN, AND USE THEREOF | Caregen Co., Ltd. | COFFA, SERGIO | 1658 | §102§112 | Non-Final OA | — | Pending | Jun 26, 2024 |
| 18719260 | METHODS FOR THE SYNTHESIS OF COMPLEMENT FACTOR D INHIBITORS AND INTERMEDIATES THEREOF | Alexion Pharmaceuticals, Inc. | ROMERO, KRISTEN WANG | §102§103Other | Non-Final OA | — | Pending | Jun 13, 2024 | |
| 18719261 | METHODS FOR THE SYNTHESIS OF COMPLEMENT FACTOR D INHIBITORS | Alexion Pharmaceuticals, Inc. | BAUER, BRIANNA LEE | §112 | Non-Final OA | — | Pending | Jun 13, 2024 | |
| 18738782 | GASTRO-RESISTANT CONTROLLED RELEASE ORAL DOSAGE FORMS | Minerva Neurosciences, Inc. | JUSTICE, GINA CHIEUN YU | 1617 | §103Other | Non-Final OA | — | Pending | Jun 10, 2024 |
| 18708275 | FLUID TREATMENT SYSTEM AND RELATED METHODS | Lignosol Ip Limited | BUSHEY, CHARLES S | 1776 | §102§103§112 | Non-Final OA | — | Pending | May 08, 2024 |
| 18655854 | COMPOSITION AND METHOD FOR MUSCLE REPAIR AND REGENERATION | Thomas Jefferson University | LEE, ANDREW P | 1691 | §102§103 | Non-Final OA | — | Pending | May 06, 2024 |
| 18653106 | METHODS OF TREATING CANCER | Inspirna, Inc. | HUTTER, GILLIAN A | 1625 | §103DP | Non-Final OA | — | Pending | May 02, 2024 |
| 18706302 | DETECTION, STAGING, MONITORING AND TREATING A DISEASE OR A CONDITION | Sunbird Bio, Inc. | BOWERS, ERIN M | 1653 | §102Other | Non-Final OA | 20d | Pending | Apr 30, 2024 |
| 18646092 | ENGINEERED TISSUE CONSTRUCTS AND USES THEREOF | Satellite Biosciences, Inc. | PELLEGRINO, BRIAN E | §102§103§112Other | Non-Final OA | — | Pending | Apr 25, 2024 | |
| 18704112 | METHODS OF IMPLANTING ENGINEERED TISSUE CONSTRUCTS | Satellite Biosciences, Inc. | JANOSKO, CHASITY PAIGE | 1613 | §103Other | Non-Final OA | 6d | Pending | Apr 24, 2024 |
| 18605744 | ASSAYS FOR ALPHA-DYSTROGLYCAN GLYCOSYLATION AND METHODS FOR USING SAME | Bridgebio Services Inc. | MONTGOMERY, ANN Y | §101§103§112 | Non-Final OA | — | Pending | Mar 14, 2024 | |
| 18691764 | SORBENTS AND METHODS FOR CARBON CAPTURE VIA CALCIUM LOOPING | UTI LIMITED PARTNERSHIP | HAILEY, PATRICIA L | §102§112 | Non-Final OA | — | Pending | Mar 13, 2024 | |
| 18691738 | SYNERGISTIC NANOMEDICINE DELIVERING TOPOISOMERASE I TOXIN (SN-38) AND INHIBITORS OF POLYNUCLEOTIDE KINASE 3'-PHOSPHATASE (PNKP) FOR ENHANCED TREATMENT OF COLORECTAL CANCER | The Governors of the University of Alberta | PROSSER, ALISSA J | 1619 | §103§112 | Non-Final OA | 53d | Pending | Mar 13, 2024 |
| 18602622 | GENE THERAPY FOR TUBEROUS SCLEROSIS | The General Hospital Corporation | VIVLEMORE, TRACY ANN | §102§112DP | Non-Final OA | — | Pending | Mar 12, 2024 | |
| 18690028 | PROCESS FOR FORMULATING COMPOSITIONS COMPRISING GLUCAGON-LIKE-PEPTIDE-2 (GLP-2) ANALOGUES | Zealand Pharma A/S | REYNOLDS, FRED H | DP | Non-Final OA | — | Pending | Mar 07, 2024 | |
| 18443987 | METHODS OF USING ACTIVIN RECEPTOR TYPE II SIGNALING INHIBITORS | Keros Therapeutics, Inc. | PRIEST, JESSICA MARIE | DP | Non-Final OA | — | Pending | Feb 16, 2024 | |
| 18683728 | PREPARATION OF LIBRARIES OF PROTEIN VARIANTS EXPRESSED IN EUKARYOTIC CELLS | Iontas Limited | FLINDERS, JEREMY C | §102§103§112 | Non-Final OA | — | Pending | Feb 14, 2024 | |
| 18681396 | SALT TOLERANT PLANTS | Rory James Hornby | PAGE, BRENT T | 1663 | §112 | Non-Final OA | — | Pending | Feb 05, 2024 |
| 18681298 | LIPID-BASED COMPOSITION FOR ORAL ADMINISTRATION OF BRADYKININ B2-RECEPTOR ANTAGONISTS | Pharvaris GmbH | TCHERKASSKAYA, OLGA V | 1615 | §112 | Final Rejection | 31d overdue | Pending | Feb 05, 2024 |
| 18293684 | MOLECULAR GLUE AND SALL4 DEGRADER | Beth Lsrael Deaconess Medical Center, Inc. | HEES, OLIVER DRAGON | 1628 | §103§112 | Non-Final OA | — | Pending | Jan 30, 2024 |
| 18393145 | Preparation Method and Enrichment Method for Cyanidin-3-Diglucoside-5-Glucoside | China Agricultural University | SWIFT, CANDICE LEE | 1657 | §103§112Other | Final Rejection | 22d | Pending | Dec 21, 2023 |
| 18571567 | PRODUCTION OF HALOGENATED ALKOXYETHANE | Commonwealth Scientific And Industrial Research Organisaton | BAHTA, MEDHANIT W | §102§103 | Non-Final OA | — | Pending | Dec 18, 2023 | |
| 18289921 | METHODS AND COMPOSITIONS FOR TREATING EPILEPSY | UNIVERSITE D'AIX-MARSEILLE | ZAHORIK, AMANDA MARY | 1636 | §112 | Non-Final OA | — | Pending | Nov 08, 2023 |
| 18289801 | COMBINATION OF PRAME SPECIFIC T CELL RECEPTORS AND CHIMERIC CO-STIMULATORY RECEPTORS | Medigene Immunotherapies GmbH | BUNNER, BRIDGET E | 1647 | §103DP | Non-Final OA | — | Pending | Nov 07, 2023 |
| 18288870 | KETAMINE AND CANNABIS FOR THE TREATMENT OF EMOTIONAL DISORDERS | Progressive Therapeutics Inc. | MELLER, MICHAEL V | 1655 | §102§103 | Non-Final OA | — | Pending | Oct 30, 2023 |
| 18012400 | CULTURE OF ORGANOIDS | Genome Research Limited | PAULUS, ERIN VIRGINIA | 1631 | §102§103§112 | Non-Final OA | — | Pending | Oct 27, 2023 |
| 18287793 | NOVEL COMPOSITIONS AND METHODS FOR TREATING CORONAVIRUS INFECTIONS | The Queensland Institute of Medical Research | BANERJEE, KOYELI | 1658 | §101§102§103§112 | Non-Final OA | — | Pending | Oct 20, 2023 |
| 18287524 | PYRIMIDO[5,4,D]PYRIMIDINE COMPOUNDS, COMPOSITIONS COMPRISING THEM AND USES THEREOF | UNIVERSITE DE MONTREAL | WEDDINGTON, KEVIN E | 1629 | §102§112 | Non-Final OA | — | Pending | Oct 19, 2023 |
| 18030740 | BIOFACTORS FOR THE TREATMENT AND PROPHYLAXIS OF DEMENTIA | Wörwag Pharma GmbH & Co.Kg | CHANDRAKUMAR, NIZAL S | 1625 | §103 | Non-Final OA | — | Pending | Oct 16, 2023 |
| 18379970 | APPARATUS AND METHOD FOR PRODUCING THREE-DIMENSIONAL OBJECTS | Q.Big 3D GmbH | TAUFIQ, FARAH N | 1754 | §101§103§112 | Non-Final OA | 58d overdue | Pending | Oct 13, 2023 |
| 18244773 | GONADOTROPIN-RELEASING HORMONE ANTAGONIST DOSING REGIMENS FOR TREATING UTERINE FIBROIDS AND REDUCING MENSTRUAL BLOOD LOSS | Kissei Pharmaceutical Co., Ltd. | COPPINS, JANET L | 1628 | §103 | Non-Final OA | 22d | Pending | Sep 11, 2023 |
| 18281346 | COMPOSITIONS AND METHODS FOR TREATING X-LINKED MYOTUBULAR MYOPATHY | Audentes Therapeutics, Inc. | DITMER, KATHRYN ELIZABETH | 3785 | §103§112 | Non-Final OA | 19d | Pending | Sep 11, 2023 |
| 18277023 | GENE THERAPY FOR DOPAMINE TRANSPORTER DEFICIENCY SYNDROME | UCL Business Ltd | TRAN, CHRISTINA L | 1637 | §101§102§103§112 | Non-Final OA | — | Pending | Aug 11, 2023 |
| 18276957 | ELECTRICAL REGENERATION OF ELECTROLYTES | President and Fellows of Harvard College | APICELLA, KARIE O | 1725 | §103 | Non-Final OA | — | Pending | Aug 11, 2023 |
| 18275849 | NGF ISOFORM FOR USE IN THE TREATMENT OF OCULAR PATHOLOGIES | Dompe' Farmaceutici Spa | FORD, VANESSA L | 1674 | §102§112 | Non-Final OA | — | Pending | Aug 04, 2023 |
| 18228818 | COMPOSITE EMBOLIZATION BEADS | Translational And Fundamental Technologies Institute LLC | TRAN, LARA LINH | 3791 | §102§103 | Non-Final OA | — | Pending | Aug 01, 2023 |
| 17625380 | MAGEA10 SPECIFIC T CELL RECEPTORS AND THEIR USE | Medigene Immunotherapies GmbH | ALLEN, MARIANNE P | 1647 | §102§103 | Non-Final OA | 17d overdue | Pending | Jul 27, 2023 |
| 18224696 | METHODS AND COMPOSITIONS FOR GENERATING ENDOTHELIAL CELLS FROM PLURIPOTENT STEM CELLS | Trailhead Biosystems Inc. | AMICK, THOMAS RUSSE | 1638 | §112 | Non-Final OA | — | Pending | Jul 21, 2023 |
| 18273395 | ANTAGONISTIC ANTI-TUMOR NECROSIS FACTOR RECEPTOR SUPERFAMILY ANTIBODIES | The General Hospital Corporation | LEE, YIE CHIA | 1642 | §102§103§112Other | Non-Final OA | — | Pending | Jul 20, 2023 |
| 18224138 | EARLY ADMINISTRATION OF LOW-DOSE COLCHICINE AFTER MYOCARDIAL INFARCTION | Institut De Cardiologie De Montreal | DAVIS, BRIAN J | 1614 | §103Other | Final Rejection | — | Pending | Jul 20, 2023 |
| 17910686 | GENE THERAPY OF NIEMANN-PICK DISEASE TYPE C | UCL Business Ltd | ABBOTT, KODYE LEE | 1634 | §103§112 | Non-Final OA | — | Pending | Jun 16, 2023 |
| 18267355 | VACCINE COMPOSITION FOR NOVEL CORONAVIRUS INFECTION | Institute Of Biophysics, Chinese Academy Of Sciences | LI, BAO Q | 1671 | §102§103Other | Non-Final OA | — | Pending | Jun 14, 2023 |
| 18256304 | METHOD OF TREATING HEREDITARY HEMORRHAGIC TELANGIECTASIA USING PAZOPANIB | Hht Foundation International, Inc. | WORSHAM, JESSICA N | 1615 | §103 | Final Rejection | 83d | Pending | Jun 07, 2023 |
| 18265178 | A FILTER UNIT, A TEXTILE TREATMENT APPARATUS, USE THEREOF AND A METHOD OF FILTERING MICROPARTICLES | Xeros Limited | SHAHINIAN, LEVON J | 1711 | §102§103 | Non-Final OA | — | Pending | Jun 02, 2023 |
| 18039846 | OLIGONUCLEOTIDES | Oxford University Innovation Limited | OLSON, ALEXANDRA NADINE | 1684 | §102§103§112Other | Non-Final OA | 33d | Pending | Jun 01, 2023 |
| 18039813 | RNA-TARGETING COMPOSITIONS AND METHODS FOR TREATING CAG REPEAT DISEASES | Astellas Gene Therapies, Inc. | VIJAYARAGHAVAN, JAGAMYA NMN | 1637 | §103§112DP | Non-Final OA | — | Pending | Jun 01, 2023 |
| 18039812 | RNA-TARGETING COMPOSITIONS AND METHODS FOR TREATING MYOTONIC DYSTROPHY TYPE 1 | Astellas Gene Therapies, Inc. | VIJAYARAGHAVAN, JAGAMYA NMN | 1633 | §103§112 | Non-Final OA | 31d overdue | Pending | Jun 01, 2023 |
| 18204342 | METHODS OF VAPOR DEPOSITION OF METAL HALIDES | Trustees Of Tufts College | PENNY, TABATHA L | 1712 | §103 | Non-Final OA | 15d overdue | Pending | May 31, 2023 |
| 18326661 | SEGMENTED GASTROINTESTINAL DEVICES AND METHODS OF USE THEREOF | Morphic Medical, Inc. | YANG, CHENG FONG | 3781 | §103 | Non-Final OA | 37d overdue | Pending | May 31, 2023 |
| 18201498 | PREFERRED ORAL TESTOSTERONE UNDECANOATE THERAPY TO ACHIEVE TESTOSTERONE REPLACEMENT TREATMENT | Marius Pharmaceuticals, Inc. | MOU, LIYUAN | 1628 | §103§112Other | Non-Final OA | 18d overdue | Pending | May 24, 2023 |
| 18037117 | SYSTEM FOR SENSING EEG SIGNALS ON A LIVING BEING, AND SYSTEM FOR ELECTRICALLY STIMULATING TISSUE OF A LIVING BEING | Precisis GmbH | BERHANU, ETSUB D | 3791 | §101§103§112 | Final Rejection | 76d | Pending | May 16, 2023 |
| 18196538 | MIR-375- AND MIR-1-REGULATED COXSACKIEVIRUS B3 HAS NO PANCREAS AND HEART TOXICITY BUT STRONG ANTITUMOR EFFICIENCY IN COLORECTAL CARCINOMAS | Technische Universität Berlin | SPENCE, JENNIFER SUZANNE | 1633 | §103 | Final Rejection | — | Pending | May 12, 2023 |
| 18036720 | METHODS FOR PURIFYING INTER-ALPHA INHIBITOR PROTEINS | Prothera Biologics, Inc. | WALLENHORST, MAUREEN | 1797 | §112 | Non-Final OA | — | Pending | May 12, 2023 |
| 18035582 | POLYSACCHARIDES FOR IV ADMINISTRATION THAT TREAT SARS-COV-2 INFECTIONS | Pharmalectin, Inc. | CHO, DAVID H | 1693 | §112 | Final Rejection | — | Pending | May 05, 2023 |
| 18035442 | FILTER UNIT, TEXTILE TREATMENT APPARATUS AND METHOD | Xeros Limited | KURTZ, BENJAMIN M | 1711 | §102§103§112 | Non-Final OA | — | Pending | May 04, 2023 |
| 18140141 | METHODS OF TREATING LYMPHOPENIA | Keros Therapeutics, Inc. | KAUFMAN, CLAIRE M | 1674 | §102§103§112 | Non-Final OA | 60d | Pending | Apr 27, 2023 |
| 18034252 | PHARMACEUTICAL PACKAGES COMPRISING POLYPROPYLENE CONTAINERS AND NGF AQUEOUS FORMULATIONS PACKAGED THEREIN | Dompe' Farmaceutici Spa | SCHLIENTZ, NATHAN W | 1616 | §103 | Final Rejection | — | Pending | Apr 27, 2023 |
| 18031772 | USE OF N-MYRISTOYL TRANSFERASE (NMT) INHIBITORS IN THE TREATMENT OF CANCER, AUTOIMMUNE DISORDERS, AND INFLAMMATORY DISORDERS | Pacylex Pharmaceuticals Inc. | VALENROD, YEVGENY | 1628 | §102 | Non-Final OA | 34d | Pending | Apr 13, 2023 |
| 18299877 | PHARMACEUTICAL COMPOSITIONS OF ANTI-CD20/ANTI-CD3 BISPECIFIC ANTIBODIES AND METHODS OF USE | Hoffmann-La Roche, Inc. | TRAN HO, LAM THUY VI | 1647 | §103DP | Final Rejection | 52d overdue | Pending | Apr 13, 2023 |
| 18030858 | POLAR LIQUIDS WITH HIGH POROSITY AND USES THEREOF | President and Fellows of Harvard College | SMARI, ABDUL-RAHMAN YUSUF WALEED | 1736 | §102§103 | Non-Final OA | 13d | Pending | Apr 07, 2023 |
| 18030876 | PEPTIDE INHIBITORS OF GLIOMA-ASSOCIATED ONCOGENE DERIVED FROM THE COILED-COIL DIMERIZATION DOMAIN OF Kif7 | The General Hospital Corporation | REYNOLDS, FRED H | 1658 | §101§112 | Non-Final OA | — | Pending | Apr 07, 2023 |
| 18030439 | CANNABINOID-CONTAINING COMPOSITIONS AND USE FOR TREATING AND PREVENTING DISEASES | Max Biology Co. Ltd. | BASQUILL, SEAN M | 1614 | §103 | Final Rejection | 15d overdue | Pending | Apr 05, 2023 |
| 18028662 | ELECTRONIC WASTE COMPOSITE ARTICLE OR MATERIAL AND PROCESS FOR MAKING SAME | Excir Works Corp. | PIRO, NICHOLAS ANTHONY | 1738 | §103 | Non-Final OA | 21d | Pending | Mar 27, 2023 |
| 18028025 | PRAME SPECIFIC T-CELL RECEPTORS AND USES THEREOF | Medigene Immunotherapies GmbH | BUTTICE, AUDREY L | 1647 | §112 | Final Rejection | 97d overdue | Pending | Mar 23, 2023 |
| 18188168 | COMBINATION TREATMENT OF AN ANTI-CD20/ANTI-CD3 BISPECIFIC ANTIBODY AND CHEMOTHERAPY | Genentech, Inc. | TRAN HO, LAM THUY VI | 1647 | §103Other | Final Rejection | — | Pending | Mar 22, 2023 |
| 18027696 | BCG VACCINATIONS FOR PREVENTION OF COVID-19 AND OTHER INFECTIOUS DISEASES | The General Hospital Corporation | GANGLE, BRIAN J | 1645 | §102Other | Final Rejection | — | Pending | Mar 22, 2023 |
| 18027506 | PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS | Achillion Pharmaceuticals, Inc. | ANDERSON, REBECCA L | 1626 | §102§103§112Other | Non-Final OA | — | Pending | Mar 21, 2023 |
| 18044747 | RIBITOL TREATMENT | The Charlotte Mecklenburg Hospital Authority D/B/A Atrium Health | NEAGU, IRINA | 1629 | §103§112DP | Non-Final OA | — | Pending | Mar 09, 2023 |
| 17924496 | COMBINATION THERAPY FOR TTR AMYLOIDOSIS | Neurimmune AG | HOWARD, ZACHARY C | 1674 | §102§103§112 | Final Rejection | 30d overdue | Pending | Mar 06, 2023 |
| 18024182 | COMPOSITIONS AND METHODS FOR TREATING THERAPY RESISTANT CANCER | The General Hospital Corporation | SHIN, DANA H | 1635 | §102§103 | Non-Final OA | — | Pending | Mar 01, 2023 |
| 18024179 | METHODS FOR IDENTIFYING CROSS-MODAL FEATURES FROM SPATIALLY RESOLVED DATA SETS | The General Hospital Corporation | TRAN, DUY ANH | 2674 | §101§102§103Other | Final Rejection | 132d overdue | Pending | Mar 01, 2023 |
| 18175224 | FILTRATION-BASED METHODS FOR PREPARING FETAL NUCLEATED RED BLOOD CELLS (NRBCS) FOR DIAGNOSTIC TESTING | Kellbenx Incorported | KIRWIN, STEFANIE JOHANNA | 1684 | §103 | Non-Final OA | — | Pending | Feb 27, 2023 |
| 18175225 | METHOD OF TREATMENT OF PATIENTS HAVING REDUCED SENSITIVITY TO A BCL-2 INHIBITOR | The Regents of the University of Colorado | KAUFMAN, CLAIRE M | 1674 | §102§103§112Other | Non-Final OA | — | Pending | Feb 27, 2023 |
| 18163810 | OBINUTUZUMAB TREATMENT OF A DLBCL PATIENT SUBGROUP | Bruker Spatial Biology, Inc. | LU, CHENG | 1642 | §103Other | Non-Final OA | 32d overdue | Pending | Feb 02, 2023 |
| 18019166 | METHODS FOR LEACHING AND RECOVERY OF PLATINUM GROUP METALS IN ORGANIC SOLVENTS | Excir Works Corp. | MCGUTHRY BANKS, TIMA MICHELE | 1733 | §112 | Final Rejection | 53d | Pending | Feb 01, 2023 |
| 18157453 | TREATMENT OF PELVIC ORGAN PROLAPSE | Remendium Labs LLC | KREMER, MATTHEW | 3791 | §112 | Non-Final OA | — | Pending | Jan 20, 2023 |
| 18016490 | INHIBITORS OF COMPLEMENT FACTOR C3 AND THEIR MEDICAL USES | Zp Spv 3 K/S | DABKOWSKI, ERINNE R | 1654 | §103§112DP | Non-Final OA | — | Pending | Jan 17, 2023 |
| 18154241 | METHODS AND COMPOSITIONS FOR TREATING EPILEPSY | Uniqure France | CHONG, KIMBERLY | 1636 | §112 | Final Rejection | — | Pending | Jan 13, 2023 |
| 18014881 | VACCINE ADJUVANTS AND METHODS OF SYNTHESIZING AND USING THE SAME | Amyris, Inc. | CHAO, ALLEN | 1622 | §102 | Final Rejection | — | Pending | Jan 06, 2023 |
| 18014701 | INTERFEROMETRIC SCATTERING CORRELATION (ISCORR) MICROSCOPY | Cambridge Enterprise Limited | AMARA, MOHAMED K | 2877 | §103 | Non-Final OA | 71d overdue | Pending | Jan 05, 2023 |
| 18014561 | COMPOSITIONS AND METHODS FOR TARGETING TUMOR ASSOCIATED TRANSCRIPTION FACTORS | BETH ISRAEL DEACONESS MEDICAL CENTER, INC. | GOMEZ RODRIGUEZ, JULIO WASHINGTON | 1637 | §103§112 | Non-Final OA | 131d overdue | Pending | Jan 05, 2023 |
| 18011999 | GENERATION OF DIVERSE VIRAL LIBRARIES | Theolytics Ltd. | BOESEN, CHRISTIAN C | 1684 | §102 | Non-Final OA | — | Pending | Dec 21, 2022 |
| 18002368 | METHOD OF TREATMENT OF INFLAMMATORY BOWEL DISEASE USING ANTI-TL1A ANTIBODIES | Pfizer, Inc. | KAUFMAN, CLAIRE M | 1674 | §103§112 | Non-Final OA | — | Pending | Dec 19, 2022 |
| 18010513 | MATURED THREE-DIMENSIONAL PRINTED COMPOSITIONS AND USES THEREOF | Auregen Biotherapeutics SA | SCHUBERG, LAURA J | 1631 | §103 | Final Rejection | 37d overdue | Pending | Dec 15, 2022 |
| 18061755 | COMPOSITIONS FOR INCREASING HALF-LIFE OF A THERAPEUTIC AGENT IN CANINES AND METHODS OF USE | Invetx, Inc. | DAHLE, CHUN WU | 1641 | §103 | Final Rejection | 7d | Pending | Dec 05, 2022 |
| 17926106 | IMMUNE CELLS WITH ENHANCED FUNCTION | The Queensland Institute of Medical Research | VAN BUREN, LAUREN K | 1638 | §102§103 | Final Rejection | — | Pending | Nov 17, 2022 |
| 17924425 | POLYNUCLEOTIDE ARRAYS | Oxford University Innovation Limited | ZHANG, KAIJIANG | 1684 | §102§112 | Non-Final OA | 30d overdue | Pending | Nov 10, 2022 |
| 17920088 | HIGHLY-NETWORKED CORONAVIRUS IMMUNOGEN COMPOSITION | Massachusetts Eye And Ear Infirmary | SPENCER, ANDREA LYNNE MORRIS | 1631 | §102§103§112 | Non-Final OA | — | Pending | Oct 20, 2022 |
| 17939198 | THERAPEUTIC AGENT FOR KERATOCONJUNCTIVE DISORDERS | Yamaguchi University | CHANDRAKUMAR, NIZAL S | 1625 | §103 | Final Rejection | 49d overdue | Pending | Sep 07, 2022 |
| 17909696 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF INTRACELLULAR BACTERIAL INFECTIONS | Endolytix Technology, Inc. | KAMM, JUDITH MARIE | 1611 | §103§112Other | Final Rejection | 7d | Pending | Sep 06, 2022 |
| 17800639 | CXCL8 (INTERLEUKIN-8) ACTIVITY INHIBITOR AND CORTICOSTEROID COMBINATION AND PHARMACEUTICAL COMPOSITION AND USE THEREOF | Dompe' Farmaceutici Spa | LEE, ANDREW P | 1691 | §103 | Non-Final OA | 19d overdue | Pending | Aug 18, 2022 |
| 17819591 | PREPARATION AND COMPOSITION OF INTER-ALPHA INHIBITOR PROTEINS FROM HUMAN PLASMA FOR THERAPEUTIC USE | Prothera Biologics, Inc. | ORWIG, KEVIN S | 3991 | §103 | Final Rejection | 16d overdue | Pending | Aug 12, 2022 |
| 17798334 | CELL CULTURE MANAGEMENT SYSTEM | Integriculture Inc. | KRCHA, MATTHEW D | 1796 | §102§112 | Non-Final OA | 42d | Pending | Aug 09, 2022 |
| 17797473 | METHODS AND COMPOSITIONS FOR PRODUCTION OF SALINE TOLERANT PLANTS | Luke Young | KUMAR, VINOD | 1663 | §103 | Final Rejection | 4d overdue | Pending | Aug 04, 2022 |
| 17875934 | COMPOSITIONS FOR INCREASING HALF-LIFE OF A THERAPEUTIC AGENT IN CANINES AND METHODS OF USE | Invetx, Inc. | PAK, MICHAEL D | 1674 | §112DPOther | Non-Final OA | — | Pending | Jul 28, 2022 |
| 17794673 | METHODS AND COMPOSITIONS FOR GENERATING TYPE 1 VESTIBULAR HAIR CELLS | Decibel Therapeutics, Inc. | TRAN, CHRISTINA L | 1637 | §112 | Non-Final OA | 62d | Pending | Jul 22, 2022 |
| 17794001 | PEPTIDE INHIBITORS OF GUANINE NUCLEOTIDE EXCHANGE FACTOR H-1 | UCL Business Ltd | KOMATSU, LI N | 1658 | §102 | Non-Final OA | — | Pending | Jul 20, 2022 |
| 17810022 | METHODS FOR THE TREATMENT OF EPILEPSY | Centre National De La Recherche Scientifique | MEYERING, SHABANA SHABBEER | 1635 | §103 | Non-Final OA | 21d | Pending | Jun 30, 2022 |
| 17843740 | PHARMACEUTICAL COMBINATION OF A THERAPEUTIC OLIGONUCLEOTIDE TARGETING HBV AND A TLR7 AGONIST FOR TREATMENT OF HBV | Hoffmann-La Roche, Inc. | POLIAKOVA-GEORGAN, EKATERINA | 1637 | §103Other | Final Rejection | — | Pending | Jun 17, 2022 |
| 17781989 | METHODS FOR DUAL DNA/PROTEIN TAGGING OF OPEN CHROMATIN | BETH ISRAEL DEACONESS MEDICAL CENTER, INC. | FLINDERS, JEREMY C | 1684 | §102§112 | Non-Final OA | — | Pending | Jun 02, 2022 |
| 17781271 | TARGETING EPHA3 AND USES THEREOF | The Queensland Institute of Medical Research | MERTZ, PREMA MARIA | 1674 | §112 | Non-Final OA | — | Pending | May 31, 2022 |
| 17825875 | COVALENT RAS INHIBITORS AND USES THEREOF | Revolution Medicines, Inc. | MARTIN, KEVIN STEPHEN | 1626 | — | Final Rejection | — | Pending | May 26, 2022 |
| 17742847 | OCULAR DEVICE DELIVERY METHODS AND SYSTEMS | Layerbio, Inc. | PIPIC, ALMA | 1617 | §103§112 | Final Rejection | 24d overdue | Pending | May 12, 2022 |
| 17774338 | DIAGNOSIS AND TREATMENT OF NAFLD AND LIVER FIBROSIS | BETH ISRAEL DEACONESS MEDICAL CENTER, INC. | WALLENHORST, MAUREEN | 1797 | §101§112 | Final Rejection | — | Pending | May 04, 2022 |
| 17735326 | COCHLEAR OUTER HAIR CELL PROMOTERS AND USES THEREOF | Decibel Therapeutics, Inc. | VIJAYARAGHAVAN, JAGAMYA NMN | 1633 | §103Other | Final Rejection | 34d | Pending | May 03, 2022 |
| 17733509 | GASTROINTESTINAL IMPLANT DELIVERY SYSTEMS AND METHODS | Gi Dynamics, Inc. | ALEMAN, SARAH WEBB | 3774 | §103§112 | Final Rejection | — | Pending | Apr 29, 2022 |
| 17731112 | METHODS FOR ELECTRO-MECHANICAL TRANSFECTION | Kytopen Corporation | NOBLE, MARCIA STEPHENS | 1632 | §101§102§112Other | Non-Final OA | 9d | Pending | Apr 27, 2022 |
| 17725271 | BIOREDUCTIVELY-ACTIVATED COMPOUNDS, THEIR PRODRUGS, RADIOPHARMACEUTICALS, THE COMPOSITIONS, AND THEIR APPLICATIONS IN MULTIMODAL THERANOSTIC MANAGEMENT OF HYPOXIA DISEASES INCLUDING CANCER | The Governors of the University of Alberta | DONOHUE, SEAN R | 1618 | §103 | Final Rejection | 29d | Pending | Apr 20, 2022 |
| 17768300 | COMPOSITIONS AND METHODS FOR MODIFYING EUKARYOTIC CELLS | Orchard Therapeutics (Europe) Limited | NOBLE, MARCIA STEPHENS | 1632 | §102§112 | Non-Final OA | 30d | Pending | Apr 12, 2022 |
| 17715724 | EXTENDED-RELEASE INJECTABLE GEL FORMULATIONS CONTAINING ANGIOTENSIN-(1-7) OLIGOPEPTIDES OR VARIANTS THEREOF | Proneurogen, Inc. | PEEBLES, KATHERINE | 1617 | §103 | Final Rejection | 60d overdue | Pending | Apr 07, 2022 |
| 17766280 | INHIBITOR OF CELL PROLIFERATION IN OBINUTUZUMAB RESISTANT CD20-POSITIVE CANCER, AND MEDICINAL COMPOSITION, MEDICINE, PRODUCTION, METHOD FOR INHIBITING CELL PROLIFERATION, THERAPEUTIC METHOD, TYPE II ANTI-CD20 ANTIBODY, COMPOUNDS, COMBINATION OF SAME, ENHANCER AND INDUCER, EACH RELATING THERETO | Chugai Seiyaku Kabushiki Kaisha | SANG, HONG | 1646 | §102§103§112 | Final Rejection | 29d | Pending | Apr 04, 2022 |
| 17689117 | METHODS OF TREATING AND DIAGNOSING DISEASE USING BIOMARKERS FOR BCG THERAPY | The General Hospital Corporation | ABBAS, SYED JARAR | 1645 | §102§112 | Non-Final OA | 14d | Pending | Mar 08, 2022 |
| 17637392 | COMPSTATIN ANALOGUES AND THEIR MEDICAL USES | Zp Spv 3 K/S | COFFA, SERGIO | 1658 | §103 | Non-Final OA | 3d overdue | Pending | Feb 22, 2022 |
| 17586277 | DUAL ATM AND DNA-PK INHIBITORS FOR USE IN ANTI-TUMOR THERAPY | Xrad Holding Cayman Limited | MAHLUM, JONATHAN DAVIS | 1625 | DP | Final Rejection | 60d overdue | Pending | Jan 27, 2022 |
| 17629918 | ADOPTIVE TRANSFER OF PLASMACYTOID DENDRITIC CELLS TO PREVENT OR TREAT HAIR LOSS | Tufts Medical Center, Inc. | MIANO, JOSEPH PAUL | 1631 | §102§103§112 | Final Rejection | 134d overdue | Pending | Jan 25, 2022 |
| 17629313 | PEPTIDE HAVING HAIR GROWTH PROMOTING ACTIVITY, AND USE THEREOF | Caregen Co., Ltd. | NIEBAUER, RONALD T | 1658 | §101§112 | Final Rejection | 3d overdue | Pending | Jan 21, 2022 |
| 17628617 | COSMETIC COMPOSITIONS AND USES THEREOF | Alumier Labs, Inc. | JOHNSON, DANIELLE D | 1617 | §103§112 | Final Rejection | 57d | Pending | Jan 20, 2022 |
| 17627854 | HOST-INDEPENDENT EXPRESSION OF BACTERIOPHAGES | Technische Universität München | WANG, RUIXUE | 1672 | §103§112 | Non-Final OA | 19d overdue | Pending | Jan 18, 2022 |
| 17627975 | SELF-ASSEMBLED VACCINES AND COMBINATION THERAPIES FOR TREATING CANCER | The General Hospital Corporation | LEE, YIE CHIA | 1642 | §103§112Other | Final Rejection | 78d | Pending | Jan 18, 2022 |
| 17625425 | LONGEVITY SIGNATURES AND THEIR APPLICATIONS | The Brigham And Women'S Hospital, Inc. | MCMILLIAN, KARA RENITA | 1623 | §102§112 | Final Rejection | — | Pending | Jan 07, 2022 |
| 17597351 | METHODS FOR THE TREATMENT OF EPILEPSY | Centre National De La Recherche Scientifique | MEYERING, SHABANA SHABBEER | 1635 | §103 | Final Rejection | 5d | Pending | Jan 04, 2022 |
| 17596491 | TARGETING DNA REPAIR IN TUMOR CELLS VIA INHIBITION OF ERCC1-XPF | The Governors of the University of Alberta | MARTIN, KEVIN STEPHEN | 1624 | §102§112 | Final Rejection | — | Pending | Dec 10, 2021 |
| 17615410 | TUMOR CELL-DERIVED EXOSOMES AND THEIR APPLICATIONS | UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION | DENT, ALANA HARRIS | 1643 | §102§103§112 | Final Rejection | 21d | Pending | Nov 30, 2021 |
| 17614460 | ANTI-GAL9 IMMUNE-INHIBITING BINDING MOLECULES | The Queensland Institute of Medical Research | LUNDE, GRACE HENRY | 1641 | §112 | Non-Final OA | — | Pending | Nov 26, 2021 |
| 17598029 | SYSTEMS AND METHODS FOR PRODUCING COLLAGEN 7 COMPOSITIONS | Phoenix Tissue Repair, Inc. | SABILA, MERCY HELLEN | 1654 | §103§112 | Non-Final OA | 89d overdue | Pending | Sep 24, 2021 |
| 17440081 | CARDIOMYOCYTE PROLIFERATION | The Queensland Institute of Medical Research | TRAN, KHOA NHAT | 1632 | §103§112 | Final Rejection | 37d overdue | Pending | Sep 16, 2021 |
| 17310235 | OLIGONUCLEOTIDES AND METHODS FOR THE TREATMENT OF AGE-RELATED MACULAR DEGENERATION | The Schepens Eye Research Institute, Inc. | PYLA, EVELYN Y | 1633 | §103 | Final Rejection | 5d overdue | Pending | Jul 27, 2021 |
| 17424985 | B CELL IMMUNOTHERAPY | Holy Cross Hospital, Inc. | TICHY, JENNIFER M.H. | 1653 | §103 | Non-Final OA | 17d overdue | Pending | Jul 22, 2021 |
| 17291192 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF ESTROGEN-DEPENDENT DISORDERS | Obseva S.A. | WELLS, LAUREN QUINLAN | 1622 | §103Other | Non-Final OA | 10d overdue | Pending | May 04, 2021 |
| 17275266 | NANOPARTICLE FORMULATIONS AND METHODS OF THEIR USE | Children'S Medical Center Corporation | MACH, ANDRE | 1615 | §103 | Non-Final OA | — | Pending | Mar 11, 2021 |
| 17257055 | COMPOSITIONS AND METHODS FOR REDUCTION OF LIPOPROTEIN A FORMATION AND TREATMENT OF AORTIC VALVE SCLEROSIS AND AORTIC STENOSIS | Abcentra, LLC | FONTAINHAS, AURORA M | 1675 | §103 | Final Rejection | 22d | Pending | Dec 30, 2020 |
| 16960221 | PROTON COUPLED ELECTROCHEMICAL CO2 CAPTURE SYSTEM | President and Fellows of Harvard College | KOLTONOW, ANDREW ROBERT | 1795 | §103§112 | Non-Final OA | — | Pending | Jul 06, 2020 |
| 16610357 | DEVICES AND METHODS FOR SENSOR-ENHANCED NEEDLE PLACEMENT | Rockport Medical Technologies LLC | DARB, HAMZA A. | 3783 | §103 | Non-Final OA | 77d overdue | Pending | Nov 01, 2019 |
| 16319849 | PEPTIDE-COATED CALCIUM PHOSPHATE PARTICLES | Cerapedics, Inc. | LEE, JIA-HAI | 1658 | §103DP | Final Rejection | — | Pending | Jan 23, 2019 |
| 15771043 | NOVEL POLYPEPTIDES WITH IMPROVED PROTEOLYTIC STABILITY, AND METHODS OF PREPARING AND USING SAME | Tufts Medical Center, Inc. | REYNOLDS, FRED H | 1658 | §103§112 | Non-Final OA | 73d overdue | Pending | Apr 25, 2018 |
IP Author helps law firms respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial